Compound: MOMELOTINIB
SMILES: O=C(NCC#N)c1ccc(-c2nc(ncc2)Nc3ccc(N4CCOCC4)cc3)cc1
InChIKey: ZVHNDZWQTBEVRY-UHFFFAOYSA-N
Synonyms: MOMELOTINIB, 1056634-68-4, Cyt387, Cyt-387, N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide, CYT-11387, momelotinibum, GS-0387, 6O01GMS00P, CYT-0387, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide, N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, CHEBI:91407, DTXSID801026049, N-(Cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide, N-(cyanomethyl)-4-[2-(4-morpholinoanilino)pyrimidin-4-yl]benzamide, N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDE, RefChem:819199, DTXCID30200399, CYT 387, CYT 11387, MFCD16038899, N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide, Momelotinib (CYT387), N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide, CHEMBL1078178, Ojjaara, Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-, Momelotinib [USAN], C23H22N6O2, Momelotinib [USAN:INN], UNII-6O01GMS00P, Omjjara, benzamide, n-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-, MOMELOTINIB [INN], Momelotinib (USAN/INN), MOMELOTINIB [WHO-DD], MLS006011154, GTPL7791, orb1307329, SCHEMBL2237234, SCHEMBL29352115, EX-A260, ZVHNDZWQTBEVRY-UHFFFAOYSA-N, GLXC-03525, HMS3244K19, HMS3244K20, HMS3244L19, HMS3295I01, HMS3655D12, HMS3744C15, CYT11387, CYT387,CYT 11387, Momelotinib (CYT387,CYT-387), BDBM50311017, EBC-11462, NSC767598, NSC800800, s2219, Momelotinib (CYT387,CYT-387)?, AKOS015904624, N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide, CCG-264946, CS-0053, DB11763, FC41383, LM-1149, NSC-767598, NSC-800800, SB14602, SDCCGSBI-0654405.P001, NCGC00244257-01, NCGC00244257-08, AC-23162, AS-19389, HY-10961, SMR004702928, SY060668, NS00072547, SW219679-1, D10315, EN300-20694510, Momelotinib (LM1149; CYT387; CYT11387), Q252602, BRD-K87737963-001-01-1, BRD-K87737963-001-06-0, BRD-K87737963-001-07-8, Z2235801913, N-(Cyanomethyl)-4-[2-[(4-morpholinophenyl)amino]-4-pyrimidinyl]benzamide, N-(cyanomethyl)-4-[2-[4-(4-morpholinyl)anilino]-4-pyrimidinyl]benzamide, N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide, CYT 11387, Cyt-387, N-(Cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide
Theoretical properties:
molecular_formula: C23H22N6O2
molecular_weight: 414.5 g/mol
exact_mass: 414.18042397 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 6
heavy_atom_count: 31
topological_polar_surface_area: 103 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: <1 mg/mL
Descriptions:
pubchem: Momelotinib is a benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis. It has a role as an antineoplastic agent, an apoptosis inducer, an anti-anaemic agent and an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor. It is a nitrile, a member of benzamides, an aminopyrimidine, a member of morpholines, a secondary amino compound and a tertiary amino compound.
chebi: A benzamide obtained by formal condensation of the carboxy group of 4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzoic acid with the primary amino group of aminoacetonitrile. It is an ATP-competitive JAK1/JAK2 inhibitor with IC<small><sub>50</sub></small> of 11 nM and 18 nM, respectively. Used for the treatment of patients with intermediate- or high-risk myelofibrosis.
wikipedia: Momelotinib, sold under the brand name Ojjaara among others, is an anticancer medication used for the treatment of myelofibrosis. It is a Janus kinase inhibitor and it is taken by mouth.
The most common adverse reactions include dizziness, fatigue, bacterial infection, hemorrhage, thrombocytopenia, diarrhea, and nausea.
Momelotinib was approved for medical use in the United States in September 2023, and in the European Union in January 2024.